Cochlear Ltd rises Tuesday, underperforms the Health Care sector
Here is the latest company close update for Cochlear Ltd, COH.
Here is the latest company close update for Cochlear Ltd, COH.
Australia’s global healthcare companies and its network of biotechnology companies will likely avoid the worst. Not so surgical gloves maker Ansell.
Cochlear chief executive Dig Howitt says tax reform and measures to boost productivity should be an election issue, as his company took a hit from cost of living pressures in the US.
David Di Pilla-led HMC eyes Brookfield-owned hospitals operator. Cochlear falls on trimmed guidance. Dividend disappointment weighs on AMP. GFG Alliance puts NSW coal mine on the block in debt plan. Mirvac soars on return to profit.
Dig Howitt says automation already plays an important role in his products, and he sees it as an enabler in achieving the mission to help people hear and be heard.
Australia can either go down a US-style push to deregulate or continue its current European-style path of increasing regulations on business, says Cochlear CEO Dig Howitt.
There is an investment mistake more painful and more costly than a 100 per cent loss and here’s what you can do to avoid it.
ASX 200 rise fades for third day running. Qantas ‘might have not survived’ without Alan Joyce and Richard Goyder: chair. WiseTech investors back founder’s reincarnation as consultant. Metcash profit warning. ResMed lifts on strong quarter earnings.
US President Joe Biden triggers oil price jump. Mesoblast top gainer. Sinopec wants price review on APLNG deal. Platinum grants Regal access for higher offer. Ratings upgrade for Cochlear. Optimism underpinning latest Bendigo Bank, UBS forecasts.
Cochlear chief executive Dig Howitt says Australia needs to increase the research and development tax incentive threshold and dust off a Morrison government-era plan.
Digital savvy seniors and an expanding body of research on the benefits of hearing to cognition underpin Cochlear’s huge long term growth trajectory, chief executive Dig Howitt says.
AUD rises on ‘quite tight’ jobs market. Cochlear, Origin sink on profit miss . Telstra rises despite profit fall. Treasury Wine lifts on China boost. Goodman dips on mixed results. Nufarm tumbles on earnings downgrade.
Investors welcome MinRes cash gains, price wins. Bellevue Gold downgraded on discounted equity raise. Inflation uptick may force RBA hike. Key exit triggers Cochlear executive rehaul.
Universities are uniquely positioned to lead very specific and ambitious ‘moonshot’ research programs aimed at solving major global problems.
Executives from Rio Tinto and Cochlear are expected to join the private event with China’s visiting foreign minister, as even business figures criticise Paul Keating’s “stupid” meeting with Wang Yi.
ASX 200 sets all-time high at close. Life360 soars 38 per cent on earnings beat. ASIC wants crime-linked Prospero wound up. China manufacturing activity better than expected but still weak.
Cochlear has delivered a bumper first half profit, but at least one analyst says the company could be doing even better than the numbers suggest.
Economy to remain resilient: Westpac. Bendigo Bank sees competition issues in ANZ’s Suncorp bid. Boral gains, Seven Group dips on takeover play. APM, A2 Milk soar.
RBA boss says lower inflation data key to unlocking rate cuts. Callide Power Trading faces court action. PwC’s Labor donation questioned. Stokes-backed Boral ups guidance.
Chimeric Therapeutics surged 12 per cent after announcing it had dosed the first leukaemia patient with its cell therapy as part of a Phase 1B clinical trial.
Iron ore miners trim gains as China’s CPI falls at fastest pace since 2009. Investors back News Corp, AGL earnings updates. Cochlear up on profit upgrade. REA Group, Transurban and Alliance Aviation drop.
Bullock says RBA not ruling anything in or out regarding rate cuts and hikes, after holds cash rate. Bullock says November hike ‘not a mistake’, and RBA doesn’t want to cut too early. ASX 200 ends lower.
CEO Dig Howitt says there is still significant, unmet and addressable clinical need for cochlear and acoustic implants, underpinning the company’s growth.
RBA November meeting ‘live’ as hints at hike. Santos lifts on LNG split calls. Bapcor dives as revenue growth slows. ACCC nod to NBN Co pricing. Fiery last AGM for Telstra chair John Mullen.
The hearing implant titan forecasts profit growth of 16 to 23 per cent in the year ahead as surgeries return to normal following three pandemic-plagued years.
CSL, Pro Medicus, Cochlear lead health sector rally. AUD at US65c after lower quarterly wages growth. China reveals more economic weakness. NAB spikes on buyback. Seek tumbles.
Small cap health stocks commonly don’t pay dividends. But these ASX players have been handing out – not burning through – cash.
Britain’s competition watchdog was due to deliver its final assessment early this week on Cochlear’s acquisition of Oticon Medical, and the deal was shaping up to get the red light.
Peter Jackson used AI to reveal ‘secret’ conversations between The Beatles in the Get Back documentary. Cochlear and Google plan to bring that technology to those hard of hearing.
Cochlear boss Dig Howitt says its wage bill hasn’t risen in line with inflation and employees understand the economics at play, as Philip Lowe issues a stern warning about big pay rises.
Original URL: https://www.theaustralian.com.au/topics/cochlear